Edition:
United States

Aurinia Pharmaceuticals Inc (AUPH.OQ)

AUPH.OQ on NASDAQ Stock Exchange Global Market

4.76USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
174,817
52-wk High
$10.54
52-wk Low
$2.03

Chart for

About

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-Aurinia Pharmaceuticals Added To The Nasdaq Biotech Index

* AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX Source text for Eikon: Further company coverage:

Dec 11 2017

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights

Nov 14 2017

BRIEF-Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​

* Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​

Oct 23 2017

BRIEF-Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise

* Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​

Oct 20 2017

BRIEF-Aurinia Pharmaceuticals reports Q2 loss per share $‍0.03​

* Aurinia reports second quarter 2017 financial results, and provides operational highlights

Aug 10 2017

BRIEF-Aurinia Pharmaceuticals resolves temporary non-compliance with Nasdaq's audit committee composition rule

* Aurinia resolves temporary non-compliance with Nasdaq's audit committee composition rule Source text for Eikon: Further company coverage:

Jul 12 2017

BRIEF-Aurinia Pharma presents voclosporin remission data

* Voclosporin remission data from the phase IIB aura-LV study highlighted at eular 2017

Jun 16 2017

Earnings vs. Estimates